temozolomide has been researched along with gpi 15427 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Alemu, C; Calvin, D; Graziani, G; Hoover, R; Lapidus, R; Leonetti, C; Morgan, L; Scarsella, M; Tang, Z; Tentori, L; Vergati, M; Woznizk, K; Xu, W; Zhang, J | 1 |
Cuzzocrea, S; Dorio, AS; Forini, O; Graziani, G; Lapidus, R; Leonetti, C; Mazzon, E; Muzi, A; Scarsella, M; Tentori, L; Vergati, M; Xu, W; Zhang, J | 1 |
2 other study(ies) available for temozolomide and gpi 15427
Article | Year |
---|---|
Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Area Under Curve; Biological Availability; Blood-Brain Barrier; Brain; Cell Line, Tumor; Central Nervous System Neoplasms; Chromatography, Liquid; Dacarbazine; Disease Models, Animal; Enzyme Inhibitors; Flow Cytometry; G2 Phase; Humans; Inhibitory Concentration 50; Kinetics; Mass Spectrometry; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Organic Chemicals; Poly(ADP-ribose) Polymerases; Rats; Rats, Sprague-Dawley; Temozolomide; Time Factors | 2005 |
Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Proliferation; Colonic Neoplasms; Colony-Forming Units Assay; Dacarbazine; Diarrhea; Drug Synergism; Enzyme Inhibitors; Intestinal Diseases; Irinotecan; Organic Chemicals; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Topoisomerase I Inhibitors; Tumor Burden | 2006 |